Dendreon gains FDA approval for prostate cancer drug Provenge

FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer

SEATTLE, April 29, 2010 /PRNewswire via COMTEX/ --Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has approved PROVENGE(R) (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). PROVENGE is designed to induce an immune response against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers, and is the first in a new therapeutic class known as autologous cellular immunotherapies.

Keep Reading at: http://investor.dendreon.com/phoenix.zhtml?c=120739&p=irol-newsArticle&ID=1420143&highlight=